지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 9 - 16 (8page)
이용수
초록· 키워드
오류제보하기
Background: Macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine with chemokine-like functions, has been shown to play a central role in several acute and chronic inflammatory diseases. However, limited information is available regarding the use of MIF as an inflammatory pathway marker in patients with tuberculosis. This study aimed to investigate the association of MIF with IFN-γ and TNF-α in active pulmonary tuberculosis (APTB) following anti-tuberculosis treatment. Methods: The MIF, TNF-α, and IFN-γ serum levels were determined in 47 patients with APTB by cytokine-specific ELISA at four phases: prior to anti-tuberculosis drug treatment (baseline), and following 2, 4, and 6 months of treatment. In addition, we measured the MIF, TNF-α, and IFN-γ serum levels in 50 health controls. Results: MIF serum levels were significantly elevated (P<0.05) in patients with APTB prior to treatment compared with that in control subjects, and TNF-α ≥449.7 pg/mL was associated with high MIF levels (≥13.1 ng/mL). MIF levels were significantly reduced (P<0.01) following 2, 4, and 6 months of treatment, with variations in TNF-α and IFN-γ serum levels. MIF levels were positively correlated with the paired TNF-α level at baseline (r=0.1103, P=0.0316) and following 6 months of treatment (r=0.09569, P=0.0364).Conclusions: A reduction in the MIF serum levels in patients with APTB following anti-tuberculosis treatment may positively affect host immune protection against Mycobacterium tuberculosis infection. Thus, serum MIF levels may constitute a useful marker for assessing therapy effectiveness in patients with APTB.
목차
등록된 정보가 없습니다.
참고문헌 (34)
참고문헌 신청
Calandra T / 2003 / Macrophage migration inhibitory factor: a regulator of innate immunity / Nat Rev Immunol 3:791~800
Gregory JL / 2006 / Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2 / J Immunol 177:8072~8079
Tillmann S / 2013 / Arrest functions of the MIF ligand/receptor axes in atherogenesis / Front Immunol 4:115
Santos LL / 2013 / Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis / Clin Chim Acta 399:1~7
Morand EF / 2006 / MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis / Nat Rev Drug Discov 5:399~410
Gregory JL / 2006 / Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2 / J Immunol 177:8072~8079
Tillmann S / 2013 / Arrest functions of the MIF ligand/receptor axes in atherogenesis / Front Immunol 4:115
Santos LL / 2013 / Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis / Clin Chim Acta 399:1~7
Morand EF / 2006 / MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis / Nat Rev Drug Discov 5:399~410
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
The Association of Higher Plasma Macrophage Migration Inhibitory Factor Levels with Lower Bone Mineral Density and Higher Bone Turnover Rate in Postmenopausal Women
Endocrinology and Metabolism
2016 .01
-
The Role of Macrophage Migration Inhibitory Factor (MIF) in Asthmatic Airway Remodeling
Allergy, Asthma & Immunology Research
2021 .01
-
Polymorphism in Macrophage Migration Inhibitory Factor -173GC in Pediatric Patients with Autoimmune Hepatitis
Pediatric Gastroenterology, Hepatology & Nutrition
2020 .01
-
Significance of Biomarkers as a Predictive Factor for Post-Traumatic Sepsis
Journal of trauma and injury : JTI
2018 .01
-
국내 의료기관 근무자에서 발생한 활동성 결핵의 양상
의료관련감염관리
2021 .12
-
Contribution of Macrophage Migration Inhibitory Factor -173G/C Gene Polymorphism to the Risk of Cancer in Chinese Population
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA
Cancer Research and Treatment
2019 .01
-
Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations
Annals of Laboratory Medicine
2017 .01
-
비인두에서 발생한 원발성 결핵 2례
Journal of Rhinology
2015 .01
-
A Case of Primary Tuberculosis of the Paranasal Sinuses
Journal of Rhinology
2024 .07
-
Modern History of Tuberculosis in Korea
Infection and Chemotherapy
2019 .01
-
Cohort Profile: Korean Tuberculosis and Post-Tuberculosis Cohort Constructed by Linking the Korean National Tuberculosis Surveillance System and National Health Information Database
예방의학회지
2022 .05
-
지역사회 폐결핵 환자의 건강정보 이해능력과 결핵 관련 지식 및 자가간호 수행도
기본간호학회지
2020 .02
-
소아청소년 결핵 접촉자 검진 및 잠복결핵감염의 치료 현황: 2014–2017 단일 기관 연구
Pediatric Infection and Vaccine
2019 .01
-
Penile Mass Caused by Mycobacterium tuberculosis
Urogenital Tract Infection
2015 .01
-
결핵환자의 결핵관련 지식, 가족지지 및 약물복용이행과의 관계
한국간호교육학회지
2022 .02
-
Asymptomatic Pulmonary Tuberculosis in Infant
Pediatric Infection and Vaccine
2017 .08
-
의료기관의 결핵관리와 제거 활동
의료관련감염관리
2023 .06
-
약제 감수성 폐결핵의 진단 및 치료의 최신 지견
대한내과학회지
2021 .10
-
Congenital Tuberculosis as a Result of Disseminated Maternal Disease: Case Report
Tuberculosis and Respiratory Diseases
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0